



Patent Application
Attorney Docket No. PC9824ACAO

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 6th day of March, 2002.

By

Deanna L. Miller

(Signature of person mailing)

Deanna L. Miller

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William J. Curatolo, et al. :

APPLICATION NO.: 09/380,885

: Examiner: S. Sharareh

FILING DATE: September 7, 1999

: Group Art Unit: 1619

TITLE: Delayed-Release Dosage Forms of Sertraline :

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Carmella A. O'Gorman

Carmella A. O'Gorman

Attorney for Applicant(s)

Reg. No. 33,749

Date: March 6, 2002

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 686-1847

TECH CENTER 1600/2900

MAR 19 2002

RECEIVED

HLS
Atkinson
4/4/02

[illegible]